Background-Prevalence and prognostic significance of abnormal P terminal force (PTF) in the general population are not known. The aim of this study was to assess the prevalence of abnormal PTF and to compare clinical outcomes of middleaged subjects with and without the PTF. Methods and Results-The presence of PTF was assessed in a cohort of 10 647 middle-aged subjects (mean age [SD], 44
T he measure P terminal force (PTF) in lead V 1 of a standard 12-lead electrocardiogram (ECG) was first introduced by Morris et al. 1 They demonstrated that the product of the duration and the amplitude of the negative terminal portion of the P-wave in lead V 1 of ≥0.04 mm•s separates patients with left-sided valvular lesions from normal subjects and reflects the severity of the disease. Since then PTF has proven to be a specific indicator of left atrial enlargement (LAE) with moderate sensitivity compared with echocardiographic left atrial measures in cardiac patients. 2, 3 PTF has also been shown to correlate with left heart filling pressures in the presence of various cardiac pathologies. 4, 5 The prognostic significance of PTF in the general population is not known. A pathological PTF is associated with adverse prognosis after myocardial infarction. 6, 7 It has also been shown to be associated with cardiac deaths in male veterans 8 and with increased mortality in male veterans in the presence of signs of left ventricular hypertrophy in the ECG. 9 On the other hand, PTF is a relatively common finding in apparently healthy middle-aged men, 10 male junior elite athletes, 11 and in healthy military recruits. 12 The aim of this study was to clarify the prognostic significance of abnormal P terminal force in the general population. In addition, we wanted to study whether PTF adds additional value to the traditional clinical and ECG risk assessment of these subjects.
Disease Study. The Coronary Heart Disease Study was part of the large Mobile Clinic Health Survey, which was performed in 35 populations of different geographical areas in Finland well representing the Finnish middle-aged population. The overall participation rate was 89.6% (total 12 310 invited subjects). We excluded subjects with unreadable or missing ECGs, subjects in whom P-wave analysis was not possible (mostly because of atrial fibrillation [AF] , atrial flutter, or pacemaker rhythm), and subjects with missing data, leaving us 10 647 subjects for data analysis. A detailed account of the study rationale and procedures performed at the baseline examinations has been described previously. 13 Briefly, a standard 12-lead ECG was recorded, and blood pressure, body mass index, and serum cholesterol were measured. Before the examination, the subjects completed a questionnaire regarding their health habits, known diseases, drug therapy, and smoking habits. All symptoms of cardiovascular disease were documented during the examination. When the original study was conducted, there were no institutional review committees, and universal practice was that subjects gave their consent by participating in the study.
Follow-Up
From the baseline examination between 1966 and 1972, the subjects were followed for 35 to 41 years until the end of 2007. Less than 2% of the subjects were lost to follow-up as a result of moving abroad, but, for the majority of this group, the survival status could be determined. The mortality data were obtained from the Causes of Death register maintained by Statistics Finland, and the death certificates were obtained for each deceased. Deaths from cardiac causes were determined based on the relevant International Classification of Diseases codes (representing I20-I25-codes in the International Classification of Diseases-10). All deaths from cardiac causes were reviewed by the use of hospital records and necropsy reports, if available, to identify sudden deaths from arrhythmia based on the definitions presented in the Cardiac Arrest Pilot Study.
14 In addition, all episodes of congestive heart failure, coronary artery disease, AF, and stroke requiring hospitalization were obtained from the Finnish Hospital Discharge Register, which includes nationwide data of all inpatient episodes in Finland at the individual level. The accuracy of the Finnish data registers used has been validated previously.
15,16

ECG Measurements
A standard 12-lead ECG was recorded with the subject at rest in supine position at paper speed of 50 mm/s and calibration of 1 mV/10 mm. The ECGs were interpreted by 9 trained readers and coded according to the revised Minnesota code. 13, 17 The PTF in lead V 1 was calculated as the product of the duration (in seconds) and amplitude (in millimeters) of the negative terminal deflection of the P-wave by a single reader as presented in Figure 1 . In addition, heart rate, PR interval, QRS duration, QTc interval, and the presence or absence of left ventricular hypertrophy (LVH) according to the SokolowLyon criteria were assessed. To ensure the reliability of ECG measurements, all 9 readers were repeatedly evaluated using reference ECG material that was not part of the ongoing study consisting of 60 ECGs, of which 50% contained abnormal findings from classes 2 to 8 of the Minnesota code. In the repeated measurements by the reader who measured the PTF, a correlation coefficient of r=0.97 was demonstrated for measuring PTF. As proposed by Morris et al, 1 a PTF value is always negative because the amplitude is added into the multiplication with a minus sign. Nonetheless, we present our results without the minus sign to enable easier interpretation. To convert the unit mm•s to mV•ms, multiply by 100.
Statistical Analysis
The differences in baseline characteristics of subjects with different degrees of PTF were assessed by ANOVA for continuous variables and chi-square test for categorical variables. Primary outcomes were allcause mortality, cardiac mortality, and arrhythmic death, and secondary outcomes were hospitalization caused by congestive heart failure, coronary heart disease, AF, and stroke. The follow-up time was defined as the number of days from the baseline examination to the day of outcome occurrence, death, or end of follow-up, whichever came first. The hazard ratios (HRs) and their 95% confidence intervals (95% CIs) were calculated using the Cox proportional hazards model for death. Because of the large amount of deaths during the follow-up, the Fine and Gray competing risks model 18 was used to calculate the HRs and their 95% CIs for cardiac death, arrhythmic death, coronary heart disease, atrial fibrillation, congestive heart failure, and stroke. In addition to age and sex, known cardiac disease, smoking, electrocardiographic LVH, systolic blood pressure, serum cholesterol, electrocardiographic signs of coronary artery disease or myocardial infarction, use of cardiac medication, heart rate, PR interval, QRS duration, and QTc interval were tested as potential confounders. The final model was formed by backward stepwise regression with all-cause mortality as the outcome. Variables with P values <0.05 were considered significant, and diastolic blood pressure was omitted because of marked collinearity with systolic blood pressure. The value of PTF as a novel risk marker was assessed by calculating the integrated discrimination improvement (IDI) values for multivariate models in which PTF was statistically significant. 19 All IDI analyses are based on corresponding Cox Proportional Hazards models because no statistical package providing this metric for Fine and Gray models was available. The statistical analyses were performed with R version 3.1.0 (http://www.R-project.com; packages cmprsk and survIDINRI) and with the Statistical Package for Social Studies, version 21 (SPSS). Bonferroni correction for 21 comparisons (3 groups and 7 end-points) for an overall α level of 0.05 yields 0.0024 as corrected α level. All P values are 2-sided.
Results
Baseline Characteristics
The baseline characteristics of subjects without PTF and with different degrees of PTF are shown in Table 1 . The prevalence of PTF 0.04 to 0.049, 0.05 to 0.059, and ≥0.06 mm•s, respectively, were 4.8%, 1.5%, and 1.2%. Subjects with abnormal PTF were generally older and had higher BMI and higher blood pressure. Baseline cardiovascular disease, use of cardiac medication, electrocardiographic LVH, and electrocardiographic signs of prior myocardial infarction and coronary artery disease became more common as PTF increased. The prevalence of PTF 0.04 to 0.049 mm•s among subjects aged 30 to 39, 40 to 49, and 50 to 59 years was 2.8%, 4.5%, and 7.5%, PTF 0.05 to 0.059 mm•s was 0.5%, 1.2%, and 3.0%, and PTF ≥0.06 mm•s was 0.5%, 1.0%, and 2.2%, respectively. ECG of a 46-year-old man free of hypertension or cardiac disease. The amplitude (a) of the negative terminal portion of the P-wave is 1 mm (0.1 mV; the baseline is slightly oblique) and the duration (d) of the negative terminal portion of the P-wave is 0.05 s (50 ms), yielding P terminal force (PTF) of 0.05 mm•s. The measurements were made from the middle of the line. The ECG showed no signs of coronary artery disease or left ventricular hypertrophy. The subject developed atrial fibrillation 30 years later, but was still alive at the end of the follow-up. An easy rule of thumb is that if the terminal negative deflection of the P-wave is >1 box (1 mm or 0.1 mV) deep and >3 boxes (60 ms) long (1.5 boxes using paper speed 25 mm/s), the PTF is distinctly abnormal (≥0.06 mm•s). Paper speed, 50 mm/s; calibration, 10 mm/ mV; small box, 1 mm; large box, 5 mm.
Risk of Death and Hospitalization
In the univariate models, PTF ≥0.04 mm•s was associated with all-cause mortality, cardiac mortality, and congestive heart failure and PTF ≥0.06 mm•s with atrial fibrillation. In the multivariate adjusted models, no clinically relevant HRs for adverse outcomes were found when PTF was <0.06 mm•s. PTF ≥0.06 mm•s was associated with an increased risk for death (HR, 1.76; 95% CI, 1.45-2.12; P<0.001) and atrial fibrillation (HR, 1.91; 95% CI, 1.34-2.73; P<0.001). No notable associations were found between PTF and sudden cardiac death and hospitalizations because of coronary heart disease or stroke. Table 2 shows the numbers and HRs for death (allcause), cardiac death, atrial fibrillation, and congestive heart failure associated with an abnormal PTF during the followup. Survival plot adjusted for confounders is presented in Figure 2 .
Subgroup Analyses
An additional analysis was conducted to assess the significance of PTF in subjects (n=8928) with no baseline cardiovascular disease and no electrocardiographic signs of myocardial infarction or coronary artery disease. In this subgroup, 391 subjects (4.4%) had PTF 0.04 to 0.049 mm•s, 111 subjects (1.2%) had PTF 0.05 to 0.059 mm•s, and 67 subjects (0.8%) had PTF ≥0.06 mm•s. As with the whole study population, subjects with abnormal PTF were older, had higher BMI, blood pressure, and heart rate, and also electrocardiographic LVH was more prevalent among these subjects, data not shown. We observed that among these subjects in univariate models, all degrees of PTF were associated with all-cause mortality, PTF ≥0.05 mm•s was associated with cardiac death, and PTF ≥0.06 mm•s was associated with atrial fibrillation and congestive heart failure. In multivariate models, PTF ≥0.06 mm•s was associated with all-cause mortality (HR, 1.44; 95% CI, 1.11-1.88; P=0.006) and with atrial fibrillation (HR, 2.38; 95% CI, 1.54-3.68; P<0.001). The analyses were also conducted separately for males and females, and the results remained largely alike. These results are provided in Tables I and II in 
Value of PTF as a Novel Risk Marker
The IDI values for the multivariate survival models in which PTF was statistically significant were calculated. In the allcause mortality model, the addition of PTF to the model with available established risk factors did not improve overall risk prediction (IDI, −0.001 (95% CI, −0.006 to 0.002; P=0.565).
In the atrial fibrillation model, risk prediction seemed to improve slightly with the addition of PTF to the model, but the change was not statistically significant (IDI, 0.001; 95% CI, −0.001 to 0.005; P=0.146). To avoid the influence of competing risk in this analysis, we also conducted it after exclusion of subjects who had died before the onset of atrial fibrillation, but the result was largely similar (IDI, 0.001; 95% CI, −0.002 to 0.004; P=0.405).
Discussion
Results of this large, prospective study with a long follow-up suggest that abnormal PTF is a relatively common finding in a standard 12-lead ECG for middle-aged subjects. Subjects presenting PTF ≥0.04 mm•s seem to be at increased risk for death, cardiac death, and congestive heart failure, and subjects presenting PTF ≥0.06 mm•s also seem to be at increased risk for atrial fibrillation. However, a major part of this association is explained by the increased burden of other risk factors in subjects presenting PTF. However, PTF ≥0.06 mm•s is associated with increased risk for death and atrial fibrillation even after adjusting for all available risk factors.
The terminal portion of the P-wave in the surface ECG mostly represents the activation of the left atrium. 20 Increases in the negative terminal portion of the P-wave in lead V 1 have been reported to be linked to left atrial hypertrophy detected by autopsy 21 and LAE detected by echocardiography. 2,3 PTF has also been shown to be related to increased left atrial pressure in chronic cardiac disease 5, 22 and in acute settings, and it seems to wear off when the clinical state improves and pressure normalizes. 4, 5 On the other hand, Josephson et al 23 observed already in 1977 that left atrial size and pressure were abnormal only in about half of the subjects with broad notched P-waves in lead II and a deep and broad PTF, but almost all subjects had prolonged interatrial conduction. It has later been shown that the left atrial activation breakthrough site is reflected to a 12-lead ECG, and left atrial activation via the Bachmann bundle creates a P-wave with a terminal negative deflection in lead V 1 . 24 This atrial activation route has been shown to be prevalent in young patients with lone AF and is related to worse prognosis and development of AF in patients with ischemic heart disease. 25, 26 A slightly abnormal PTF has been a relatively frequent finding also in studies conducted in normally healthy populations. In an early study by Forfang and Erikssen, the prevalence of abnormal PTF (defined as ≥0.03 mm•s) was 7% in apparently healthy middle-aged men. 10 Recently, normal reference values for PTF have been provided from a population free of clinically apparent cardiovascular disease or major cardiovascular risk factors. 27 In that study, the 95% reference range for PTF among middle-aged white subjects was 0 to 0.044 mm•s, and it extended up to 0.048 and 0.059 among males and females over 65 years of age, respectively. PTF is also a common finding among young subjects, with a reported prevalence of PTF ≥0.04 mm•s being 14% among junior elite athletes 11 and 3.2% in healthy military recruits. 12 As in previous studies, PTF ≥0.04 mm•s was a relatively common finding in our study, with a prevalence of 7.5% in the whole population and 6.4% among subjects with no overt cardiac disease.
PTF has been shown to predict mortality after myocardial infarction, 6 and the relationship persists even after adjusting for left ventricular ejection fraction. 7 It has also been shown in a large ECG-archive-based study on male veterans that PTF predicts cardiovascular deaths (HR, 1.47) 8 and the relationship strengthens when PTF presents with electrocardiographic LVH (HR, 3.5). 9 However, because of the design of these studies, no adjustments for baseline clinical status could be made.
Thus, PTF is a rather specific marker of LAE with moderate sensitivity. 2, 3 This provides 1 explanation for why we and others [6] [7] [8] [9] have found an association between abnormal PTF and adverse outcomes, given that LAE is linked to death, stroke, congestive heart failure, AF, and left ventricular diastolic dysfunction. 28 As LAE is associated with incident AF, it is possible that the adverse effect of PTF on mortality is mediated solely by increased risk of AF, given the 2-fold risk of death and over 3-fold risk of heart failure and stroke generally associated with AF. 29, 30 However, another potential explanation may be that PTF in these patients is a marker of a subclinical structural cardiac disease leading to left atrial volume overload, which is then translated into reduced survival. This is supported by a recent study that showed that PTF correlated with blood pressure, but the relationship was attenuated when adjusted for left ventricular mass. 31 PTF can turn out to be a useful indicator of ones risk of developing AF. Our study failed to show improvement in risk prediction based on the small and nonsignificant IDI values. However, one should interpret these values with caution because it is possible that subjects free of PTF at the baseline examination have developed PTF during the follow-up as a result of left atrial overload, eventually leading to atrial fibrillation. Established risk factors for AF include various structural cardiac conditions, such as systolic or diastolic left ventricular dysfunction, left ventricular hypertrophy, valvular heart disease, and myocardial infarction, but also cardiovascular risk factors, such as hypertension, smoking, and diabetes mellitus, are associated with incident AF. 32 In the present study, the risk factors for AF were significantly more prevalent among subjects with PTF compared with the rest of the cohort. Thus, in univariate analysis, individuals with PTF had significantly elevated morbidity and mortality rates. Remarkably, an almost 2-fold risk of AF persisted in the present study even after adjusting for all available potential confounding factors. This indicates that PTF is not just associated with underlying cardiovascular risk factors and structural heart disease, but represents more specifically changes in the atrial structure and function that independently contribute to the prognosis. Increased atrial fibrosis together with electric remodeling and structural alterations, associated with increased left atrial pressure and dilatation, are important in the development of AF. 32 The increased magnitude of the negative terminal portion of the P wave in V 1 seems to be a marker for some of these changes.
The strengths of our study are the large population size and the long follow-up times, with only a small fraction of subjects lost to follow-up. The measurements of P wave in our study were performed using standard 12-lead ECG recordings, which are commonly available in clinical practice. The main weakness of our study is that various subclinical cardiac conditions might not have been revealed because we did not have echocardiographic data. However, this is similar to everyday clinical practice in which clinical history with findings together with an ECG still form the basis for patient evaluation. Further research is required to clarify the complex relationship between PTF, left atrial size, left atrial pressure, atrial conduction, left ventricular properties, and clinical outcomes.
This study indicates that a distinctly abnormal PTF is associated with increased mortality and high risk of AF also in a middle-aged general population without overt heart disease. However, one should interpret PTF with caution, especially among younger patients with no other signs of cardiovascular disease. Based on our results, PTF ≥0.06 mm•s should be considered pathological also in the general population and warrants closer clinical evaluation of the subjects with this ECG abnormality, even in those without a known cardiovascular disease. Furthermore, PTF over 0.04 mm•s but under 0.06 mm•s can provide additional information in clinical risk stratification among patients with other risk factors for cardiovascular disease. 
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None. Survival plot for death (all-cause), adjusted for age, sex, body mass index, baseline cardiovascular disease, use of cardiac medication, systolic blood pressure, smoking, cholesterol, heart rate, electrocardiographic left ventricular hypertrophy, electrocardiographic signs of myocardial infarction, and electrocardiographic signs of coronary artery disease. No separate curves are provided for P terminal force (PTF) 0.04 to 0.049 and 0.05 to 0.059 as they were practically overlapping with the curve of the normal group.
